Raymond James has added Tenet Healthcare (THC) to the firm’s “Analyst Current Favorites” list given the firm’s view of “an attractive risk/reward scenario” given what it sees as Tenet’s long-term growth potential and room for multiple expansion. The firm’s recent meetings with management “leave us incrementally bullish on the company’s prospects,” says Raymond James, which has a Strong Buy rating and $95 price target on Tenet shares. Simultaneously, the firm is removing Cigna (CI) from the Analyst Current Favorites as they believe Tenet “currently offers a more attractive risk/reward scenario.” The firm continues to rate Cigna a Strong Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on THC:
- Greenlight buys Seadrill, cuts Teck in Q2
- Tenet Healthcare names CEO Saum Sutaria as Chairman of the Board
- Tenet Healthcare price target raised to $98 from $92 at Credit Suisse
- Tenet Healthcare price target raised to $87 from $84 at RBC Capital
- Tenet Healthcare price target raised to $104 from $95 at UBS